WAM
CLDI icon

Wolverine Asset Management’s Calidi Biotherapeutics CLDI Stock Holding History

Wolverine Asset Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-150
Closed -$176K – 2149
2022
Q3 		$176K Sell
150
-2,578
-95% -$3.09M ﹤0.01% 1271
2022
Q2 		$3.25M Buy
2,728
+7
+0.3% +$8.34K 0.03% 425
2022
Q1 		$3.23M Buy
2,721
+1,163
+75% +$1.37M 0.03% 400
2021
Q4 		$1.83M Buy
+1,558
New +$1.84M 0.02% 580

Other funds holding CLDI

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
EC
Elequin Capital New York $1.19B AUM 16.08% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return

Wolverine Asset Management's CLDI Position: Q4 2022 in Review

Wolverine Asset Management sold out of Calidi Biotherapeutics (CLDI) in Q4 2022, closing a stake of 150 shares — an estimated $176K sold.

Wolverine Asset Management first reported a position in CLDI in Q4 2021 and held it in 4 quarters. The position peaked at $3.25M in Q2 2022. 24 funds tracked by Wall St. Rank hold CLDI as of Q4 2022.

  • Wolverine Asset Management reported no remaining Calidi Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Wolverine Asset Management sold 150 Calidi Biotherapeutics shares in Q4 2022, an estimated $176K.
  • Wolverine Asset Management first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 4 quarters.
  • Wolverine Asset Management's Calidi Biotherapeutics position peaked at $3.25M in Q2 2022.
  • 24 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q4 2022.

Based on Wolverine Asset Management's 13F filing for Q4 2022, filed 1 Feb 2023.